FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Treatment of Refractory or Relapsed Primary Mediastinal Large B

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S.

QR Code
Embed the QR code on your website:
Download
Copy